120 related articles for article (PubMed ID: 15209436)
1. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
2. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
3. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
4. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
5. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
Cloos PA; Fledelius C
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504
[TBL] [Abstract][Full Text] [Related]
6. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.
Cloos PA; Christgau S; Lyubimova N; Body JJ; Qvist P; Christiansen C
Breast Cancer Res; 2003; 5(4):R103-9. PubMed ID: 12818000
[TBL] [Abstract][Full Text] [Related]
9. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
Kawana K; Takahashi M; Hoshino H; Kushida K
Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
[TBL] [Abstract][Full Text] [Related]
11. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
12. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
[TBL] [Abstract][Full Text] [Related]
13. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
[TBL] [Abstract][Full Text] [Related]
14. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
15. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
[TBL] [Abstract][Full Text] [Related]
16. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
17. Urinary markers of type I collagen degradation in the dog.
Allen MJ; Allen LC; Hoffmann WE; Richardson DC; Breur GJ
Res Vet Sci; 2000 Oct; 69(2):123-7. PubMed ID: 11020362
[TBL] [Abstract][Full Text] [Related]
18. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
19. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis.
Garnero P; Delmas PD
Bone; 2003 Jan; 32(1):20-6. PubMed ID: 12584032
[TBL] [Abstract][Full Text] [Related]
20. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
